<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34985276</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>1867</StartPage><EndPage>1882</EndPage><MedlinePgn>1867-1882</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.1c01255</ELocationID><Abstract><AbstractText>Hybrid compounds containing structural fragments of the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids were designed with the aid of docking and molecular mechanics studies. Following the synthesis of the compounds using a peptide-coupling methodology, they were characterized for their ROCK2 inhibition, radical scavenging, effects on cell viability (MTT assay), and NRF2 induction (luciferase assay). One of the compounds (<b>1d</b>) was selected in view of its good multitarget profile and good tolerability. It was able to induce the NRF2 signature, promoting the expression of the antioxidant response enzymes HO-1 and NQO1, via a KEAP1-dependent mechanism. Analysis of mRNA and protein levels of the NRF2 pathway showed that <b>1d</b> induced the NRF2 signature in control and <i>SOD1</i>-ALS lymphoblasts but not in sALS, where it was already increased in the basal state. These results show the therapeutic potential of this compound, especially for ALS patients with a <i>SOD1</i> mutation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mart&#xed;n-C&#xe1;mara</LastName><ForeName>Olmo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Unidad de Qu&#xed;mica Org&#xe1;nica y Farmac&#xe9;utica, Departamento de Qu&#xed;mica en Ciencias Farmac&#xe9;uticas, Facultad de Farmacia, Universidad Complutense, Plaza de Ram&#xf3;n y Cajal sn, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arribas</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas "Alberto Sols" UAM-CSIC, Department of Biochemistry, School of Medicine, and Institute Te&#xf3;filo Hernando for Drug Discovery, Universidad Aut&#xf3;noma de Madrid, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-0253-911X</Identifier><AffiliationInfo><Affiliation>UCL School of Pharmacy, University College London, 29/39 Brunswick Square, London WC1N 1AX, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales-Tenorio</LastName><ForeName>Marcos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Requero</LastName><ForeName>&#xc1;ngeles</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porras</LastName><ForeName>Gracia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2707-8110</Identifier><AffiliationInfo><Affiliation>Centro de Investigaciones Biol&#xf3;gicas Margarita Salas, CSIC, Ramiro de Maeztu 9, 28040 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giorgi</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Unidad de Qu&#xed;mica Org&#xe1;nica y Farmac&#xe9;utica, Departamento de Qu&#xed;mica en Ciencias Farmac&#xe9;uticas, Facultad de Farmacia, Universidad Complutense, Plaza de Ram&#xf3;n y Cajal sn, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Alvarado</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Unidad de Qu&#xed;mica Org&#xe1;nica y Farmac&#xe9;utica, Departamento de Qu&#xed;mica en Ciencias Farmac&#xe9;uticas, Facultad de Farmacia, Universidad Complutense, Plaza de Ram&#xf3;n y Cajal sn, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lastres-Becker</LastName><ForeName>Isabel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Instituto de Investigaciones Biom&#xe9;dicas "Alberto Sols" UAM-CSIC, Department of Biochemistry, School of Medicine, and Institute Te&#xf3;filo Hernando for Drug Discovery, Universidad Aut&#xf3;noma de Madrid, 28029 Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, 28031 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Men&#xe9;ndez</LastName><ForeName>J Carlos</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-0560-8416</Identifier><AffiliationInfo><Affiliation>Unidad de Qu&#xed;mica Org&#xe1;nica y Farmac&#xe9;utica, Departamento de Qu&#xed;mica en Ciencias Farmac&#xe9;uticas, Facultad de Farmacia, Universidad Complutense, Plaza de Ram&#xf3;n y Cajal sn, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003373">Coumaric Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016166">Free Radical Scavengers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C431364">KEAP1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000072019">Kelch-Like ECH-Associated Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495635">NFE2L2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>84477-87-2</RegistryNumber><NameOfSubstance UI="D019307">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C515852">ROCK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q0CH43PGXS</RegistryNumber><NameOfSubstance UI="C049347">fasudil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019307" MajorTopicYN="N">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003373" MajorTopicYN="N">Coumaric Acids</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016166" MajorTopicYN="N">Free Radical Scavengers</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072019" MajorTopicYN="N">Kelch-Like ECH-Associated Protein 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054460" MajorTopicYN="N">rho-Associated Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no
competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>5</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34985276</ArticleId><ArticleId IdType="pmc">PMC9132363</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01255</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zarei S.; Carr K.; Reiley L.; D&#xed;az K.; Guerra O.; Fern&#xe1;ndez-Altamirano P.; Pagani W.; Lodin D.; Orozco G.; Chinea A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015, 6, 171.10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O.; Al-Chalabi A.; Chio A.; Corr E. M.; Logroscino G.; Robberecht W.; Shaw P. J.; Simmons Z.; van den Berg L. H. Nat. Rev. Dis. Primers 2017, 3, 17071.10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C.; Newton J.; Lonergan K.; Chiwera T.; Booth T.; Chandran S.; Colville S.; Heverin M.; Mays I.; Pal S.; Pender N.; Pinto-Grau M.; Radakovic R.; Shaw C. E.; Stephenson L.; Swingler R.; Vajda A.; Al-Chalabi A.; Hardiman O.; Abrahams S. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology 2018, 91, e1370&#x2013;e1380. 10.1212/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J.; Pender N. P.; Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007, 6, 994&#x2013;1003. 10.1016/S1474-4422(07)70265-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D. R.; Siddique T.; Patterson D.; Figlewicz D. A.; Sapp P.; Hentati A.; Donaldson D.; Goto J.; O&#x2019;Regan J. P.; Deng H.-X.; Rahmani Z.; Krizus A.; McKenna-Yasek D.; Cayabyab A.; Gaston S. M.; Berger R.; Tanzi R. E.; Halperin J. J.; Herzfeldt B.; Van den Bergh R.; Hung W.-Y.; Bird T.; Deng G.; Mulder D. W.; Smyth C.; Laing N. G.; Soriano E.; Pericak-Vance M. A.; Haines J.; Rouleau G. A.; Gusella J. S.; Horvitz H. R.; Brown R. H. Jr. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 364, 362.10.1038/364362c0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364362c0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad A.; Bharathi V.; Sivalingam V.; Girdhar A.; Patel B. K. Molecular mechanisms of TDP-43, misfolding and pathology in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019, 12, 25.10.3389/fnmol.2019.00025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00025</ArticleId><ArticleId IdType="pmc">PMC6382748</ArticleId><ArticleId IdType="pubmed">30837838</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D.; Mansfield C.; Moussy A.; Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?. Front. Aging Neurosci. 2017, 9, 68.10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan M. C.; Vucic S.; Talbot K.; McDermott C. J.; Hardiman O.; Shefner J. M.; Al-Chalabi A.; Huynh W.; Cudkowicz M.; Talman P.; Van den Berg L. H.; Dharmadas T.; Wicks P.; Reilly C.; Turner M. R. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2021, 17, 104&#x2013;118. 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J. S.; Genge A.; Chio A.; Estol C. J.; Chaverri D.; Hern&#xe1;ndez M.; Mar&#xed;n S.; Mascias J.; Rodr&#xed;guez G. E.; Povedano M.; Paipa A.; Dom&#xed;nguez R.; Gamez J.; Salvado M.; Lunetta C.; Ballario C.; Riva N.; Mandrioli J.; Moussy A.; Kinet J. P.; Auclair C.; Dubreuil P.; Arnold V.; Mansfield C. D.; Hermine O.; Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotrophic Lateral Scler. Frontotemporal Degener. 2020, 21, 5&#x2013;14. 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart A.; Sandercock J.; Bryan S.; Hyde C.; Barton P. M.; Fry-Smith A.; Burls A. The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review. Health Technol. Assess. 2001, 5, 1&#x2013;97. 10.3310/hta5020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta5020</ArticleId><ArticleId IdType="pubmed">11809124</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara H.; Tanaka H. Treatment and early diagnosis of amyotrophic lateral sclerosis (ALS). Farumashia 2013, 49, 945&#x2013;949.</Citation></Reference><Reference><Citation>Carri M. T.; Grignaschi G.; Bendotti C. Targets in ALS: designing multidrug therapies. Trends Pharmacol. Sci. 2006, 27, 267&#x2013;273. 10.1016/j.tips.2006.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2006.03.009</ArticleId><ArticleId IdType="pubmed">16690390</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankiewicz T. R.; Pena C.; Bouchard R. J.; Linsemanc D. A. Dysregulation of Rac or Rho elicits death of motor neurons and activation of these GTPases is altered in the G93A mutant hSOD1 mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2020, 136, 104743.10.1016/j.nbd.2020.104743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104743</ArticleId><ArticleId IdType="pmc">PMC7020796</ArticleId><ArticleId IdType="pubmed">31931138</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P.; T&#xf6;nges L.. Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis. PCT Int. Appl., WO 2013135596 A1 20130919, 2013.</Citation></Reference><Reference><Citation>Bermel C.; T&#xf6;nges L.; Planchamp V.; Gillardon F.; Weishaupt J. H.; Dietz G. P.; B&#xe4;hr M.; Lingor P. Combined inhibition of Cdk 5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Mol. Cell. Neurosci. 2009, 42, 427&#x2013;437. 10.1016/j.mcn.2009.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2009.09.005</ArticleId><ArticleId IdType="pubmed">19782753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P.; Teusch N.; Schwarz K.; M&#xfc;ller R.; Mack H.; B&#xe4;hr M.; M&#xfc;ller B. K. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J. Neurochem. 2007, 103, 181&#x2013;189. 10.1111/j.1471-4159.2007.04756.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04756.x</ArticleId><ArticleId IdType="pubmed">17608642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P.; T&#xf6;nges L.; Pieper N.; Bermel C.; Barski E.; Planchamp V.; B&#xe4;hr M. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain 2008, 131, 250&#x2013;263. 10.1093/brain/awm284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm284</ArticleId><ArticleId IdType="pubmed">18063589</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowerman M.; Murray L. M.; Boyer J. G.; Anderson C. L.; Kothary R. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Med. 2012, 10, 24.10.1186/1741-7015-10-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-10-24</ArticleId><ArticleId IdType="pmc">PMC3310724</ArticleId><ArticleId IdType="pubmed">22397316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingor P.; Weber M.; Camu W.; Friede T.; Hilgers R.; Leha A.; Neuwirth C.; G&#xfc;nther R.; Benatar M.; Kuzma-Kozakiewicz M.; Bidner H.; Blankenstein C.; Frontini R.; Ludolph A.; Koch J. C.; ROCK-ALS: Protocol for a randomized, placebo-controlled, double-blind phase iia trial of safety, tolerability and efficacy of the rho kinase (ROCK) inhibitor fasudil in amyotrophic lateral sclerosis. Front. Neurol. 2019, 10, 293.10.3389/fneur.2019.00293.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00293</ArticleId><ArticleId IdType="pmc">PMC6446974</ArticleId><ArticleId IdType="pubmed">30972018</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch J. C.; Kuttler J.; Maass F.; Lengenfeld T.; Zielke E.; B&#xe4;hr M.; Lingor P. Compassionate use of the ROCK inhibitor fasudil in three patients with amyotrophic lateral sclerosis. Front. Neurol. 2020, 11, 173.10.3389/fneur.2020.00173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00173</ArticleId><ArticleId IdType="pmc">PMC7083210</ArticleId><ArticleId IdType="pubmed">32231638</ArticleId></ArticleIdList></Reference><Reference><Citation>Vomund S.; Sch&#xe4;fer A.; Parnham M. J.; Br&#xfc;ne B.; Von Knethen A. Nrf2, the master regulator of anti-oxidative responses. Int. J. Mol. Sci. 2017, 18, 2772.10.3390/ijms18122772.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18122772</ArticleId><ArticleId IdType="pmc">PMC5751370</ArticleId><ArticleId IdType="pubmed">29261130</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong K. I.; Padmanabhan B.; Kobayashi A.; Shang C.; Hirotsu Y.; Yokoyama S.; Yamamoto M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol. Cell. Biol. 2007, 27, 7511&#x2013;7521. 10.1128/MCB.00753-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00753-07</ArticleId><ArticleId IdType="pmc">PMC2169061</ArticleId><ArticleId IdType="pubmed">17785452</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A.; Manda G.; Hassan A.; Alcaraz M. J.; Barbas C.; Daiber A.; Ghezzi P.; Le&#xf3;n R.; L&#xf3;pez M. G.; Oliva B.; Pajares M.; Rojo A. I.; Robledinos-Ant&#xf3;n N.; Valverde A. M.; Guney E.; Schmidt H. H. H. W. Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach. Pharmacol. Rev. 2018, 70, 348&#x2013;383. 10.1124/pr.117.014753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.117.014753</ArticleId><ArticleId IdType="pubmed">29507103</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A.; Rojo A. I.; Wells G.; Hayes J. D.; Cousin S. P.; Rumsey W. L.; Attucks O. C.; Franklin S.; Levonen A. L.; Kensler T. W.; Dinkova-Kostova A. T. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug. Discovery 2019, 18, 295&#x2013;317. 10.1038/s41573-018-0008-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-018-0008-x</ArticleId><ArticleId IdType="pubmed">30610225</ArticleId></ArticleIdList></Reference><Reference><Citation>Rada P.; Rojo A. I.; Evrard-Todeschi N.; Innamorato N. G.; Cotte A.; Jaworski T.; Tob&#xf3;n-Velasco J. C.; Devijver H.; Garc&#xed;a-Mayoral M. F.; Van Leuven F.; Hayes J. D.; Bertho G.; Cuadrado A. Structural and functional characterization of Nrf2 degradation byglycogen synthase kinase 3/&#x3b2;-TrCP. Free Radical Biol. Med. 2015, 88, 147&#x2013;157. 10.1016/j.freeradbiomed.2015.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.04.029</ArticleId><ArticleId IdType="pmc">PMC3422007</ArticleId><ArticleId IdType="pubmed">22751928</ArticleId></ArticleIdList></Reference><Reference><Citation>Cores &#xc1;.; Piquero M.; Villacampa M.; Le&#xf3;n R.; Men&#xe9;ndez J. C. Nrf2 regulation processes as a source of potential drug targets against neurodegenerative diseases. Biomolecules 2020, 10, 904.10.3390/biom10060904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10060904</ArticleId><ArticleId IdType="pmc">PMC7356958</ArticleId><ArticleId IdType="pubmed">32545924</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarlette A.; Krampfl K.; Grothe C.; Neuhoff N.; Dengler R.; Petri S. Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2008, 67, 1055&#x2013;1062. 10.1097/NEN.0b013e31818b4906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818b4906</ArticleId><ArticleId IdType="pubmed">18957896</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S.; K&#xf6;rner S.; Kiaei M. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurol. Res. Int. 2012, 2012, 878030.10.1155/2012/878030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/878030</ArticleId><ArticleId IdType="pmc">PMC3461296</ArticleId><ArticleId IdType="pubmed">23050144</ArticleId></ArticleIdList></Reference><Reference><Citation>Posa D.; Mart&#xed;nez-Gonz&#xe1;lez L.; Bartolom&#xe9; F.; Nagaraj S.; Porras G.; Mart&#xed;nez A.; Mart&#xed;n-Requero &#xc1;. Recapitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients. Mol. Neurobiol. 2019, 56, 2424&#x2013;2432. 10.1007/s12035-018-1249-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1249-8</ArticleId><ArticleId IdType="pubmed">30030753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I.; Porras G.; Arribas-Bl&#xe1;zquez M.; Maestro I.; Borrego-Hern&#xe1;ndez D.; Boya P.; Cerd&#xe1;n S.; Garc&#xed;a-Redondo A.; Mart&#xed;nez A.; Mart&#xed;n-Requero &#xc1;. Molecular alterations in sporadic and SOD1-ALS immortalized lymphocytes: towards a personalized therapy. Int. J. Mol. Sci. 2021, 22, 3007.10.3390/ijms22063007.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22063007</ArticleId><ArticleId IdType="pmc">PMC8000750</ArticleId><ArticleId IdType="pubmed">33809456</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S.; K&#xf6;rner S.; Kiaei M. Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS. Neurol. Res. Int. 2012, 878030, 1.10.1155/2012/878030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/878030</ArticleId><ArticleId IdType="pmc">PMC3461296</ArticleId><ArticleId IdType="pubmed">23050144</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay R. R.; Popovic-Nikolic M.; Nikolic K.; Uliassi E.; Bolognesi M. L. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 2018, 7, 3.10.1186/s40169-017-0181-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-017-0181-2</ArticleId><ArticleId IdType="pmc">PMC5770353</ArticleId><ArticleId IdType="pubmed">29340951</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindy M.; Lupinacci P.; Chau R.; Shum T.; Ko D. A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C). F1000Research 2017, 6, 230.10.12688/f1000research.10519.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.10519.1</ArticleId><ArticleId IdType="pmc">PMC6051227</ArticleId><ArticleId IdType="pubmed">30057745</ArticleId></ArticleIdList></Reference><Reference><Citation>Swindell W. R.; Bojanowski K.; Kindy M. S.; Chau R. M. W.; Ko D. GM604 regulates developmental neurogenesis pathways and the expression of genes associated with amyotrophic lateral sclerosis. Transl. Neurodegener. 2018, 7, 30.10.1186/s40035-018-0135-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-018-0135-7</ArticleId><ArticleId IdType="pmc">PMC6276193</ArticleId><ArticleId IdType="pubmed">30524706</ArticleId></ArticleIdList></Reference><Reference><Citation>Golko-Perez S.; Amit T.; Moussa B. H.; Weinreb Y. O. Beneficial effects of multitarget iron chelator on central nervous system and gastrocnemius muscle in SOD1(G93A) transgenic ALS Mice. J. Mol. Neurosci. 2016, 59, 504&#x2013;510. 10.1007/s12031-016-0763-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-016-0763-2</ArticleId><ArticleId IdType="pubmed">27173029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.; Yin W.; Tu Y.; Wang S.; Yang X.; Chen Q.; Zhang X.; Han Y.; Pi R. L-F001, a novel multifunctional ROCK inhibitor, suppresses neuroinflammation in vitro and in vivo: Involvement of NF-&#x3ba;B inhibition and Nrf2 pathway activation. Eur. J. Pharmacol. 2017, 806, 1&#x2013;9. 10.1016/j.ejphar.2017.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2017.03.025</ArticleId><ArticleId IdType="pubmed">28320516</ArticleId></ArticleIdList></Reference><Reference><Citation>Daina A.; Michielin O.; Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717.10.1038/srep42717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42717</ArticleId><ArticleId IdType="pmc">PMC5335600</ArticleId><ArticleId IdType="pubmed">28256516</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong G.; Wu Z.; Yi J.; Fu L.; Yang Z.; Hsieh C.; Yin M.; Zeng X.; Wu C.; Lu A.; Chen X.; Hou T.; Cao D. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021, 49, W5&#x2013;W14. 10.1093/nar/gkab255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab255</ArticleId><ArticleId IdType="pmc">PMC8262709</ArticleId><ArticleId IdType="pubmed">33893803</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland S.; Bourin A.; Alen J.; Geraets J.; Schroeders P.; Castermans K.; Kindt N.; Boumans N.; Panitti L.; Fransen S.; Vanormelingen J.; Stassen J. M.; Leysen D.; Defert O. Design, synthesis, and biological evaluation of novel, highly active soft rock inhibitors. J. Med. Chem. 2015, 58, 4309&#x2013;4324. 10.1021/acs.jmedchem.5b00308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b00308</ArticleId><ArticleId IdType="pubmed">25898023</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaguchi H.; Kasa M.; Amano M.; Kaibuchi K.; Hakoshima T. Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. Structure 2006, 14, 589&#x2013;600. 10.1016/j.str.2005.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2005.11.024</ArticleId><ArticleId IdType="pubmed">16531242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari R.; Kumar R.; Lynn A. g_mmpbsa&#x2014;A GROMACS Tool for High-Throughput MM-PBSA Calculations. J. Chem. Inf. Model. 2014, 54, 1951&#x2013;1962. 10.1021/ci500020m.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci500020m</ArticleId><ArticleId IdType="pubmed">24850022</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.; Liu A.; Ouyang Y.; Huang Y.; Chao X.; Pi R. Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders?. Expert Opin. Invest. Drugs 2013, 22, 537&#x2013;550. 10.1517/13543784.2013.778242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.2013.778242</ArticleId><ArticleId IdType="pubmed">23461757</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch J. C.; Tatenhorst L.; Roser A.-E.; Saal K.-A.; T&#xf6;nges L.; Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol. Ther. 2018, 189, 1&#x2013;21. 10.1016/j.pharmthera.2018.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2018.03.008</ArticleId><ArticleId IdType="pubmed">29621594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H.; Gao N.; Tian X.; Liu T.; Fang Y.; Zhou J.; Wen Q.; Xu B.; Qi B.; Gao J.; Li H.; Jia L.; Quiao H. Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. Sci. Rep. 2015, 5, 17671.10.1038/srep17671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep17671</ArticleId><ArticleId IdType="pmc">PMC4669488</ArticleId><ArticleId IdType="pubmed">26635233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nan Z.; Hao C.; Ye X.; Feng Y.; Sun R. Interaction of graphene oxide with bovine serum albumin: A fluorescence quenching study. Spectrochim. Acta, Part A 2019, 210, 348&#x2013;354. 10.1016/j.saa.2018.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.saa.2018.11.028</ArticleId><ArticleId IdType="pubmed">30476875</ArticleId></ArticleIdList></Reference><Reference><Citation>Epps D. E.; Raub T. J.; Caiolfa V.; Chiari A.; Zamai M. Determination of the affinity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fluorescence of the protein. J. Pharm. Pharmacol. 1999, 51, 41&#x2013;48. 10.1211/0022357991772079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/0022357991772079</ArticleId><ArticleId IdType="pubmed">10197416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedov I.; Nikiforova A.; Khaibrakhmanova D. Binding constants of clinical drugs and other organic ligands with human and mammalian serum albumins. Biophysica 2021, 1, 344&#x2013;358. 10.3390/biophysica1030026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biophysica1030026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A.; Mart&#xed;n-Moldes Z.; Ye J.; Lastres-Becker I. Transcription factors NRF2 and NF-&#x3ba;B are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation. J. Biol. Chem. 2014, 289, 15244&#x2013;15258. 10.1074/jbc.M113.540633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.540633</ArticleId><ArticleId IdType="pmc">PMC4140883</ArticleId><ArticleId IdType="pubmed">24759106</ArticleId></ArticleIdList></Reference><Reference><Citation>Herpers B.; Wink S.; Fredriksson L.; Di Z.; Hendriks G.; Vrieling H.; de Bont H.; van de Water B. Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-&#x3ba;B activation and sensitizes toward TNF&#x3b1;-induced cytotoxicity. Arch. Toxicol. 2016, 90, 1163&#x2013;1179. 10.1007/s00204-015-1536-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-015-1536-3</ArticleId><ArticleId IdType="pmc">PMC4830895</ArticleId><ArticleId IdType="pubmed">26026609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan X.; Jiang X.; He Y.; Zhong F.; Li X.; Xiong Z.; Li Z.; Liu X.; Cui C.; Zhao Q.; Xie Y.; Yang F.; Wu C.; Shen J.; Zheng M.; Wang Z.; Jiang H. Automated design and optimization of multitarget schizophrenia drug candidates by deep learning. Eur. J. Med. Chem. 2020, 204, 112572.10.1016/j.ejmech.2020.112572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.112572</ArticleId><ArticleId IdType="pubmed">32711293</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M.; Singh A.; Macri K.; Reynolds C.; Singhal V.; Biswal S.; Spannhake E. W. Antioxidant components of naturally-occurring oils exhibit marked anti-inflammatory activity in epithelial cells of the human upper respiratory system. Respir. Res. 2011, 12, 92.10.1186/1465-9921-12-92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1465-9921-12-92</ArticleId><ArticleId IdType="pmc">PMC3154159</ArticleId><ArticleId IdType="pubmed">21752292</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastra D.; Fern&#xe1;ndez-Gin&#xe9;s R.; Manda G.; Cuadrado A.. Perspectives on the clinical development of NRF2-targeting drugs. In: Schmidt H. H. H. W.; Ghezzi P.; Cuadrado A. (eds) Reactive oxygen species. Network pharmacology and therapeutic applications. Handbook of Experimental Pharmacology2021, 264, 93&#x2013;141, Springer.</Citation><ArticleIdList><ArticleId IdType="pubmed">32776282</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam J.; Cook J. L. How many transcription factors does it take to turn on the heme oxygenase-1 gene?. Am. J. Respir. Cell Mol. Biol. 2007, 36, 166&#x2013;174. 10.1165/rcmb.2006-0340TR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2006-0340TR</ArticleId><ArticleId IdType="pubmed">16990612</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris E. H.; Giasson B. I.; Hodara R.; Xu S.; Trojanowski J. Q.; Ischiropoulos H.; Lee V. M.-Y. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 2005, 280, 21212&#x2013;21219. 10.1074/jbc.M412621200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M412621200</ArticleId><ArticleId IdType="pubmed">15817478</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel H. A.; Hartley D. M.; Balakhaneh D.; Aggarwal A.; Teichberg S.; Callaway D. J. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer&#x2019;s disease. J. Biol. Chem. 2002, 277, 42881&#x2013;42890. 10.1074/jbc.M206593200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M206593200</ArticleId><ArticleId IdType="pubmed">12167652</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giovanni S.; Eleuteri S.; Paleologou K. E.; Yin G.; Zweckstetter M.; Carrupt P. A.; Lashuel H. A. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J. Biol. Chem. 2010, 285, 14941&#x2013;14954. 10.1074/jbc.M109.080390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.080390</ArticleId><ArticleId IdType="pmc">PMC2865316</ArticleId><ArticleId IdType="pubmed">20150427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito S.; Sugumaran M.; Wakamatsu K. Chemical reactivities of ortho-quinones produced in living organisms: fate of quinonoid products formed by tyrosinase and phenoloxidase action on phenols and catechols. Int. J. Mol. Sci. 2020, 21, 6080.10.3390/ijms21176080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21176080</ArticleId><ArticleId IdType="pmc">PMC7504153</ArticleId><ArticleId IdType="pubmed">32846902</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G.-Z.; Wang Z.-J.; Bai F.; Qin X.-J.; Cao J.; Lv J.-Y.; Zhang M.-S. Epigallocatechin-3-gallate protects HUVECs from PM2.5-induced oxidative stress injury by activating critical antioxidant pathways. Molecules 2015, 20, 6626&#x2013;6639. 10.3390/molecules20046626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules20046626</ArticleId><ArticleId IdType="pmc">PMC6272777</ArticleId><ArticleId IdType="pubmed">25875041</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Z.-Y.; Lu M.-C.; Xu L.-L.; Yang T.-T.; Xi M.-Y.; Xu X.-L.; Guo X.-K.; Zhang X.-J.; You Q.-D.; Sun H.-P. Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. J. Med. Chem. 2014, 57, 2736&#x2013;2745. 10.1021/jm5000529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm5000529</ArticleId><ArticleId IdType="pubmed">24512214</ArticleId></ArticleIdList></Reference><Reference><Citation>Baird L.; Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell. Biol. 2020, 40, e00099&#x2013;e00020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296212</ArticleId><ArticleId IdType="pubmed">32284348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricouart A.; Gesquiere J. C.; Tartar A.; Sergheraert C. Design of potent protein kinase inhibitors using the bisubstrate approach. J. Med. Chem. 1991, 34, 73&#x2013;78. 10.1021/jm00105a012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00105a012</ArticleId><ArticleId IdType="pubmed">1992155</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O.; Olson A. J. Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2012, 31, 455&#x2013;461. 10.1002/jcc.21334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21334</ArticleId><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham M. J.; van der Spoel D.; Lindahl E.; Hess B.; GROMACS development team , GROMACS User Manual version 2018.4, www.gromacs.org (2018).</Citation></Reference><Reference><Citation>Lee J.; Cheng X.; Swails J. M.; Yeom M. S.; Eastman P. K.; Lemkul J. A.; Wei S.; Buckner J.; Jeong J. C.; Qi Y.; Jo S.; Pande V. S.; Case D. A.; Brooks C. L. III; MacKerell A. D. Jr.; Klauda J. B.; Im W. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. J. Chem. Theory Comput. 2016, 12, 405&#x2013;413. 10.1021/acs.jctc.5b00935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.5b00935</ArticleId><ArticleId IdType="pmc">PMC4712441</ArticleId><ArticleId IdType="pubmed">26631602</ArticleId></ArticleIdList></Reference><Reference><Citation>Antolovich M.; Prenzler P. D.; Patsalides E.; McDonald S.; Robards K. Methods for testing antioxidant activity. Analyst 2002, 127, 183&#x2013;198. 10.1039/b009171p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/b009171p</ArticleId><ArticleId IdType="pubmed">11827390</ArticleId></ArticleIdList></Reference><Reference><Citation>Plank D. W.; Szpylka J.; Sapirstein H.; Woollard D.; Zapf Z. M.; Lee V.; Chen C.-Y. O.; Liu R. H.; Tsao R.; D&#xfc;sterloh A.; Baugh S. Determination of antioxidant activity in foods and beverages by reaction with 2,2-diphenyl-1-picrylhydrazyl (DPPH): Collaborative study first action 2012.04. J. AOAC Int. 2012, 95, 1562&#x2013;1569. 10.5740/jaoacint.CS2012_04.</Citation><ArticleIdList><ArticleId IdType="doi">10.5740/jaoacint.CS2012_04</ArticleId><ArticleId IdType="pubmed">23451369</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra K.; Ojha H.; Chaudhury N. K. Estimation of antiradical properties of antioxidants using DPPH assay: A critical review and results. Food Chem. 2012, 130, 1036&#x2013;1043. 10.1016/j.foodchem.2011.07.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foodchem.2011.07.127</ArticleId></ArticleIdList></Reference><Reference><Citation>De las Cuevas N.; Mu&#xf1;oz U.; Bartolom&#xe9; F.; Esteras N.; Alquezar C.; Mart&#xed;n-Requero A. Cell cycle and Alzheimer&#x2019;s disease: Studies in non-neuronal cells. J. Appl. Biomed. 2010, 8, 121&#x2013;130. 10.2478/v10136-009-0015-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/v10136-009-0015-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B. R.; Miller R. G.; Swash M.; Munsat T. L. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler. Other Mot. Neuron Disord. 2000, 1, 293&#x2013;299. 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai Y.; Pathak R.; Kumari N.; Sah D. K.; Pandey S.; Kalra N.; Soni R.; Dwarakanath B. S.; Bhatt A. N. Mitochondrial biogenesis and metabolic hyperactivation limits the application of MTT assay in the estimation of radiation induced growth inhibition. Sci. Rep. 2018, 8, 1531.10.1038/s41598-018-19930-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19930-w</ArticleId><ArticleId IdType="pmc">PMC5784148</ArticleId><ArticleId IdType="pubmed">29367754</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo A. I.; Salinas M.; Mart&#xed;n D.; Perona R.; Cuadrado A. J. Neurosci. 2004, 24, 7324&#x2013;7334. 10.1523/JNEUROSCI.2111-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2111-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729771</ArticleId><ArticleId IdType="pubmed">15317858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lastres-Becker I.; Innamorato N. G.; Jaworski T.; R&#xe1;bano A.; K&#xfc;gler S.; Van Leuven F.; Cuadrado A. Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain 2014, 137, 78&#x2013;91. 10.1093/brain/awt323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt323</ArticleId><ArticleId IdType="pubmed">24277722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>